Cargando…
Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event
Autores principales: | Adhikari, Narayan, Kumar, Pavnesh, Venkatesulu, Bhanu P., Pandey, Rambha, Haresh, Kunhiparambath P., Gupta, Subhash, Sharma, Daya N., Rath, Goura K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223377/ https://www.ncbi.nlm.nih.gov/pubmed/30241172 http://dx.doi.org/10.1200/JGO.2016.007765 |
Ejemplares similares
-
Metabolic toxicities in patients undergoing treatment for nonhematological malignancy: A cross-sectional study
por: Gupta, Subhash, et al.
Publicado: (2016) -
Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature
por: Kreitman, Kyle, et al.
Publicado: (2020) -
Can Chemotherapy be Integrated with Brachytherapy in Locally Advanced Carcinoma Cervix- A Proof of Principle Study
por: Gupta, Subhash, et al.
Publicado: (2019) -
Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment
por: Charville, Gregory W., et al.
Publicado: (2018) -
High-dose-rate interstitial brachytherapy for liver metastases: first study from India
por: Sharma, Daya Nand, et al.
Publicado: (2013)